Drug Profile
BAT 8001
Alternative Names: Anti-ErbB2 antibody drug conjugate - Bio-Thera Solutions; Anti-HER2 antibody drug conjugate - Bio-Thera Solutions; BAT-8001Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Bio-Thera Solutions
- Class Antineoplastics; Biological toxins; Drug conjugates; Immunoconjugates; Maytansinoids
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Breast cancer
- Phase I/II Solid tumours
- No development reported Gastric cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Gastric-cancer in China (IV, Injection)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)
- 10 Dec 2019 Updated efficacy and adverse events data from a phase I trial in Breast Cancer presented at the 42nd Annual San Antonio Breast Cancer Symposium (SABCS-2019)